Ozempic injection label updated with three type 2 diabetes indications

The prescribing information for Ozempic (semaglutide) injection was updated on the DailyMed drug labeling site on June 1, 2026 ^[1]. The label carries three approved uses in adults with type 2 diabetes. Ozempic is indicated as an add-on to diet and exercise to improve blood sugar, to reduce the risk of major adverse cardiovascular events in adults who also have established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults who also have chronic kidney disease ^[1].

The page shows the label information updated June 1, 2026, while the revision line inside the document reads "Revised: 5/2026" ^[1].

What the label says about dosing

Ozempic is given once weekly at any time of day, with or without meals, by injection under the skin of the abdomen, thigh or upper arm ^[1]. The label's step-up schedule starts at 0.25 mg once weekly. After four weeks, the dose goes to 0.5 mg once weekly. If more blood sugar control is needed, the dose can go to 1 mg once weekly after at least four weeks at 0.5 mg, and then to 2 mg once weekly after at least four weeks at 1 mg ^[1].

For the kidney and cardiovascular risk-reduction use, the label describes a different target: increase to 1 mg once weekly after at least four weeks at 0.5 mg ^[1].

The drug comes in single-patient-use pens at 2 mg/3 mL (0.68 mg/mL), 4 mg/3 mL (1.34 mg/mL) and 8 mg/3 mL (2.68 mg/mL), and in single-dose prefilled syringes at 0.25 mg, 0.5 mg or 1 mg per 0.5 mL ^[1]. If a dose is missed, the label says to give it within five days of the missed dose ^[1]. Ozempic injection was first approved in the United States in 2017 ^[1].

Safety information in the label

Ozempic carries a boxed warning about thyroid C-cell tumors. Semaglutide caused these tumors in rodents, and the label states it is unknown whether Ozempic causes them, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent findings has not been determined ^[1]. The drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[1].

The warnings section lists acute pancreatitis, diabetic retinopathy complications, hypoglycemia when used with insulin or an insulin secretagogue, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious allergic reactions including anaphylaxis and angioedema, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation ^[1]. The label says Ozempic is not recommended in patients with severe gastroparesis and that a pen should never be shared between patients, even if the needle is changed ^[1]. The most common side effects, reported in at least 5 percent of patients, are nausea, vomiting, diarrhea, abdominal pain and constipation ^[1].

The label also notes that Ozempic delays stomach emptying, which can affect how oral medicines are absorbed, and says women should stop the drug at least two months before a planned pregnancy because of its long washout period ^[1].

The most recent major change listed in the document is a revision to the severe gastrointestinal adverse reactions section, dated 10/2025 ^[1]. The label does not include an indication for weight loss or obesity, and the updated document does not describe any change to the drug's boxed warning or to its approved patient population ^[1].

Why it matters for patients

This label is the document U.S. clinicians, pharmacists and insurers read to decide who can get Ozempic and under what conditions. Because it separates three type 2 diabetes uses, coverage decisions can hinge on which one applies to a given patient — for example, whether someone has established cardiovascular disease or chronic kidney disease alongside diabetes ^[1].

The dose steps matter in practice. The label ties the cardiovascular and kidney risk-reduction use to a 1 mg weekly dose reached after at least four weeks at 0.5 mg, while blood sugar control can continue up to 2 mg weekly ^[1]. It also spells out that missed doses can be given within five days, which differs from simply skipping to the next scheduled day ^[1].

The label does not explain what changed for prescribers in this specific update beyond the text shown, and no separate FDA announcement of the revision has been reported. It also does not say whether the cardiovascular and kidney indications are new, expanded or unchanged from earlier versions, and no information has been disclosed on whether other semaglutide products, such as Wegovy or Rybelsus, were updated at the same time ^[1].

What happens next

The label carries a June 1, 2026 update date and a "Revised: 5/2026" line ^[1]. No further label changes or FDA actions have been announced.